Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Blair William & Co. IL

Blair William & Co. IL decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 42.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,145 shares of the company's stock after selling 25,173 shares during the quarter. Blair William & Co. IL owned about 0.11% of Medpace worth $11,344,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in Medpace in the fourth quarter valued at $30,000. SBI Securities Co. Ltd. acquired a new position in Medpace during the fourth quarter worth about $31,000. Jones Financial Companies Lllp lifted its holdings in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. Lindbrook Capital LLC grew its holdings in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares during the last quarter. Finally, True Wealth Design LLC lifted its position in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company's stock valued at $56,000 after acquiring an additional 168 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Robert W. Baird lifted their price objective on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Leerink Partners initiated coverage on shares of Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target for the company. Finally, Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $376.30.

Remove Ads

Medpace Stock Up 4.0 %

Shares of MEDP stock traded up $11.85 during mid-day trading on Wednesday, reaching $309.58. The company's stock had a trading volume of 265,500 shares, compared to its average volume of 301,591. The company's 50 day simple moving average is $334.26 and its 200-day simple moving average is $338.52. The firm has a market capitalization of $9.43 billion, a PE ratio of 24.51, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12-month low of $289.01 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.